Chiome Bioscience Inc.
4583・Growth Market・Pharmaceuticals
Governance
In March 2025, the company transitioned from a company with a board of corporate auditors to a company with an audit and supervisory committee. The Board of Directors consists of 7 directors (including 4 outside directors, an outside ratio of approximately 57%), and the Audit and Supervisory Committee consists of 3 members, all of whom are outside directors. The Annual Securities Report does not mention the establishment of a Nomination Committee or Compensation Committee.
Risk Management
Strategic management risks are analyzed by the responsible director and department heads, and deliberated at management meetings and Board of Directors meetings. A risk management table has been established, and a system is in place to report and share management-related risks in general, including sustainability risks, at Board of Directors meetings and other venues on a quarterly basis. Advice from external experts such as lawyers, certified public accountants, and patent attorneys is also utilized.
Shareholder Returns
Annual dividends for both FY2025 (ending December 2025) and FY2026 (ending December 2026) are ¥0. The company maintains a no-dividend policy due to continued net losses. No share buybacks have been conducted.
Dividend Policy
The annual dividend for FY2025 (ending December 2025) is ¥0 (year-end dividend of ¥0). The forecast annual dividend for FY2026 (ending December 2026) is also ¥0. Company-wide earnings forecasts are undisclosed because it is difficult to make reasonable earnings projections for the Drug Discovery Business. Given ongoing quarterly net losses, the company will continue its no-dividend policy for the time being.
ESG
The company is advancing sustainability initiatives centered on human capital acquisition and development. As of the end of December 2025, the proportion of female managers stood at 30.0%, and the gender pay gap for regular employees was disclosed at 84.8%. It has introduced a flextime system and stock option/restricted stock compensation plans to promote work-life balance and employee retention. Specific numerical targets have not yet been set at this time.
Last updated: March 27, 2026